
    
      IPI 926 is an inhibitor of the Hedgehog Pathway. IPI-926 in combination with gemcitabine may
      improve therapeutic outcomes in patients with pancreatic cancer. Infinity is conducting a
      Phase 1b/2 clinical trial to evaluate the safety and efficacy of IPI-926 in combination with
      gemcitabine in patients with previously untreated metastatic pancreatic cancer.
    
  